All In MedTech

FDA Clearance Tracker · P250023

Allurion™ Gastric Balloon System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Feb 20, 2026

Approved

Time to decision

235 days

Received Jun 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P250023
Device name
Allurion™ Gastric Balloon System
Applicant location
Natick, MA
Received
Jun 30, 2025
Decided
Feb 20, 2026
Decision
Approved
Supplements
2 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LTI

FDA's approval statement

As written in FDA's record.

Approval for the Allurion Gastric Balloon System (AGBS) is indicated to promote short-term limited weight loss in adult individuals with obesity between the ages of 22 years and 65 years with a body mass index (BMI) greater than or equal to 30 kg/m2 and less than or equal to 40 kg/m2 who have had at least one unsuccessful attempt at a weight loss program. The residence time for each AGBS is variable with an average observed residence time of 15.3 weeks. The AGBS is to be used in conjunction with a moderate intensity lifestyle modification therapy program. The AGBS consists of up to two Allurion Balloons placed during a 10-month period.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LTI. The earliest in FDA's data is P840025-S001, decided Dec 18, 1985.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Allurion Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.